BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Stealth BioTherapeutics Initiates Phase III Study of Elamipretide in Patients with Primary Mitochondrial Myopathy

  Pivotal trial to evaluate treatment for disease with no FDA-approved treatment options

  November 6, 2017

   · 

  3 min read
• BioMidwest

  Moleculera Labs Issued Key U.S. Patent Covering the Company’s Diagnostic Panel for Infection-Induced Autoimmune Neuropsychiatric Disorders

  Moleculera Labs, today announced that a key patent has issued covering the company’s Cunningham Panel and its use in helping physicians identify whether an individual’s neurologic and/or psychiatric symptoms could be caused by an autoimmune dysfunction.

  November 6, 2017

   · 

  2 min read
• Business

  Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results

  November 6, 2017

   · 

  10 min read
• Drug Development

  The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

  The Medicines Company today announced the initiation of the Phase III clinical program for inclisiran, with the commencement of patient dosing on November 1, 2017 in the ORION-11 trial.

  November 6, 2017

   · 

  16 min read
• Pharm Country

  Artemis Therapeutics Receives Orphan Drug Designation From FDA for Artemisone for the Treatment of Malaria

  Artemis is now qualified to receive significant benefits throughout its orphan drug development program including more frequent FDA interactions, protocol assistance, and tax credits for clinical research costs.

  November 6, 2017

   · 

  3 min read
• Drug Development

  Flex Pharma Reports Positive Topline Data From Exploratory Phase II Trial of FLX-787 in ALS

  The study was terminated early to focus the Company’s resources on the ongoing US Phase 2b ALS study (COMMEND).

  November 6, 2017

   · 

  7 min read
• Drug Development

  Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation

  Findings suggest molecules from the company’s vIgD platform could potentially have clinical therapeutic utility in multiple inflammatory diseases.

  November 6, 2017

   · 

  5 min read
• Business

  Translate Bio Appoints Ann Barbier, M.D., Ph.D., as Chief Medical Officer

  Translate Bio today announced the appointment of Ann Barbier, M.D., Ph.D., as chief medical officer, effective immediately.

  November 6, 2017

   · 

  2 min read
• Drug Development

  UroGen Pharma Announces First Patient Enrolled in Allergan Phase II Clinical Trial of RTGel in Combination With BOTOX for the Treatment of Overactive Bladder

  The trial is being conducted by Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, under the terms of a license agreement with UroGen Pharma.

  November 6, 2017

   · 

  5 min read
• Drug Development

  BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax

  The Phase I/IIa study evaluates the safety and activity of BriaVax in patients with advanced breast cancer. To boost the anti-tumor effects of BriaVax.

  November 6, 2017

   · 

  6 min read